SARS-coronavirus (SARS-CoV) genome expression depends on the synthesis of a set of mRNAs, which presumably are capped at their 59 end and direct the synthesis of all viral proteins in the infected cell. Sixteen viral non-structural proteins (nsp1 to nsp16) constitute an unusually large replicase complex, which includes two methyltransferases putatively involved in viral mRNA cap formation. The S-adenosyl-L-methionine (AdoMet)-dependent (guanine-N7)-methyltransferase (N7-MTase) activity was recently attributed to nsp14, whereas nsp16 has been predicted to be the AdoMet-dependent (nucleoside-29O)-methyltransferase. Here, we have reconstituted complete SARS-CoV mRNA cap methylation in vitro. We show that mRNA cap methylation requires a third viral protein, nsp10, which acts as an essential trigger to complete RNA cap-1 formation. The obligate sequence of methylation events is initiated by nsp14, which first methylates capped RNA transcripts to generate cap-0 7Me GpppA-RNAs. The latter are then selectively 29O-methylated by the 29O-MTase nsp16 in complex with its activator nsp10 to give rise to cap-1 7Me GpppA 29OMe -RNAs. Furthermore, sensitive in vitro inhibition assays of both activities show that aurintricarboxylic acid, active in SARS-CoV infected cells, targets both MTases with IC 50 values in the micromolar range, providing a validated basis for anti-coronavirus drug design.
Introduction
In 2003, the severe acute respiratory syndrome coronavirus (SARS-CoV), which was likely transmitted from bats, was responsible for a worldwide SARS-outbreak [1] . Coronaviruses belong to the order Nidovirales and are characterized by the largest positive-strand RNA ((+) RNA) genomes (around 30,000 nt) known in the virus world. The enzymology of their RNA synthesis is therefore thought to be significantly more complex than that of other RNA virus groups [2, 3, 4] . The 59-proximal two-thirds of the CoV genome (open reading frames 1a and 1b) are translated into the viral replicase polyproteins pp1a and pp1ab (Figure 1 ), which give rise to 16 nonstructural proteins (nsps) by co-and posttranslational autoproteolytic processing. The 39-proximal third encodes the viral structural proteins and several so-called accessory proteins, which are expressed from a set of four to nine subgenomic (sg) mRNAs. The latter are transcribed from subgenome-length minus-strand templates, whose production involves a unique mechanism of discontinuous RNA synthesis (reviewed by [5, 6] ). To organize their complex RNA synthesis and genome expression, the CoV proteome includes several enzyme activities that are rare or lacking in other (+) RNA virus families (reviewed in [2] ). In the years following the 2003 SARS outbreak, bioinformatics, structural biology, (reverse) genetics and biochemical studies have contributed to the in-depth characterization of CoV nsps in general and those of SARS-CoV in particular [7] . Currently documented enzyme activities include two proteinases (in nsp3 and nsp5; [8, 9] ), a putative RNA primase (nsp8; [10] ), an RNA-dependent RNA polymerase (nsp12; [11, 12] ), a helicase/ RNA triphosphatase (nsp13; [13, 14] ), an exo-and an endoribonuclease (nsp14 and nsp15; [15, 16] , and an S-adenosyl-Lmethionine (AdoMet)-dependent (guanine-N7)-methyltransferase (N7-MTase), which were proposed to play a role in the formation of CoV mRNA caps (nsp14; [17] ). Based on comparative sequence analysis, nsp16 presumably encodes an AdoMet-dependent mRNA cap (nucleoside-29O)-methyltransferase (29O-MTase) [3, 18, 19] . For SARS-CoV nsp16, however, this enzyme activity has remained elusive thus far, and experimental evidence for its existence has only been obtained for the related feline coronavirus (FCoV) nsp16 [18] . CoV nsps form the viral replication/ transcription complex (RTC), which is thought to localize to a network of endoplasmic reticulum-derived, modified membranes in the infected cell [20, 21] . Protein-protein interactions were proposed to be essential for the assembly of the RTC and may therefore also regulate the activities of enzymes involved in viral RNA synthesis.
Although the 59 ends of SARS-CoV mRNAs have not been characterized yet, they are assumed to carry a cap structure. This assumption is based on the characterisation of genomic and subgenomic mRNAs of the coronavirus murine hepatitis virus (MHV) [22, 23] and the related equine torovirus (EToV or Berne virus), which also belong to the Coronaviridae family [23, 24] . The mRNAs of both viruses were concluded to carry a 59-terminal cap structure. Moreover, in the coronavirus and torovirus genome three enzymes putatively involved in mRNA capping have been identified, although they remain poorly characterised [13, 14, 17, 18, 19] . Cap structures promote initiation of translation and protect mRNAs against exoribonuclease activities [25, 26, 27] . The synthesis of the cap structure in eukaryotes involves three sequential enzymatic activities: (i) an RNA triphosphatase (RTPase) that removes the 59 cphosphate group of the mRNA; (ii) a guanylyltransferase (GTase) which catalyzes the transfer of GMP to the remaining 59-diphosphate terminus; and (iii) an N7-MTase that methylates the cap guanine at the N7-position, thus producing the so-called ''cap-0 structure '', 7Me GpppN. Whereas lower eukaryotes, including yeast, employ a cap-0 structure, higher eukaryotes convert cap-0 into cap-1 or cap-2 structures [25, 26, 28] by means of 29O-MTases, which methylate the ribose 29O-position of the first and the second nucleotide of the mRNA, respectively. RNA cap methylation is essential since it prevents the pyrophosphorolytic reversal of the guanylyltransfer reaction, and ensures efficient binding to the ribosome [25, 26] . In the case of (+) RNA viruses such as alphaviruses and flaviviruses, mutations in RNA cap methylation genes were shown to be lethal or detrimental to virus replication [29, 30, 31, 32, 33] . For coronaviruses, a functional and genetic analysis performed on MHV temperature sensitive mutants mapping to the N7-MTase domain of CoV nsp14 and in the 29O-MTase nsp16 indicated that both are involved in positive-strand RNA synthesis by previously formed replicase-transcriptase complexes [11] . The importance of nsp14 and nsp16 for viral RNA synthesis is further supported by data obtained by mutagenesis of Figure 1 . Genomic organization of CoV pp1a/pp1ab and location of the nsp14 and nsp16 mutants. The SARS-CoV genomic RNA is translated in two large polyproteins, pp1a and pp1ab following a -1 ribosomal frame shift. The two polyproteins are then cleaved by viral proteases in order to produce 16 nsps (nsp1 to nsp11 from pp1a and nsp1 to nsp16 from pp1ab). Positions of the point mutants used in this study are indicated. White triangles are used for positions targeting exonuclease motifs of nsp14 and black triangles are used for positions targeting MTase motifs of nsp14 and nsp16 (the putative AdoMet binding site of nsp14 and catalytic tetrad of nsp16). doi:10.1371/journal.ppat.1000863.g001
Author Summary
In 2003, an emerging coronavirus (CoV) was identified as the etiological agent of severe acute respiratory syndrome (SARS). SARS-CoV replicates and transcribes its large RNA genome using a membrane-bound enzyme complex containing a variety of viral nonstructural proteins. A critical step during RNA synthesis is the addition of a cap structure to the newly produced viral mRNAs, ensuring their efficient translation by host cell ribosomes. Viruses generally acquire their cap structure either from cellular mRNAs (e.g., ''cap snatching'' of influenza virus) or employ their own capping machinery, as is supposed to be the case for coronaviruses. mRNA caps synthesized by viruses are structurally and functionally undistinguishable from cellular mRNAs caps. In coronaviruses, methylation of mRNA caps seems to be essential, since mutations in viral methyltransferases nsp14 or nsp16 render non-viable virus. We have discovered an unexpected key role for SARS-CoV nsp10, a protein of previously unknown function, within mRNA cap methylation. Nsp10 induces selective 29O-methylation of guanine-N7 methylated capped RNAs through direct activation of the otherwise inactive nsp16. This finding allows the full reconstitution of the SARS-CoV mRNA cap methylation sequence in vitro and opens the way to exploit the mRNA cap methyltransferases as targets for anti-coronavirus drug design.
MTase catalytic residues in SARS-CoV RNA replicon systems [17, 30] .
In the case of coronaviruses, the machinery putatively involved in equipping both genome and subgenomic mRNAs with a cap-1 structure is thought to consist of (i) the multifunctional nsp13, which may contribute the RTPase activity of the helicase domain [13, 34] , (ii) a still unknown GTase, (iii) the C-terminal domain of nsp14, which was recently identified as the N7-MTase [17] and (iv) nsp16, the putative 29O-MTase [3, 17, 18] .
Using mammalian and yeast two-hybrid systems as well as pulldown assays, it was shown that SARS-CoV nsp14 and nsp16 specifically interact with nsp10 [35, 36] suggesting that nsp10 may play a role in the viral capping pathway. The crystal structure of nsp10, a small RNA-binding protein that contains two zinc fingers, was recently solved [37, 38] , but its role and mode of action in the viral replicative cycle remains elusive. In view of the phenotype of some mouse hepatitis virus (MHV) mutants, a role in viral RNA synthesis was postulated [11, 39] , but other studies implicated nsp10 in replicase polyprotein processing [40] . SARS-CoV nsp10 was also shown to bind single-and double-strand RNA and DNA with low affinity and without obvious sequence specificity [37] .
In this study, we report the discovery of a function for SARSCoV nsp10 as an essential factor to trigger full nsp16 29O-MTase activity. We deciphered the RNA cap methylation sequence where the guanine-N7-methylation by nsp14 necessarily precedes the 29O-methylation by the nsp10/nsp16 pair. The SARS-CoV nsp10/nsp14/nsp16 trio constitutes an attractive target package for antiviral drug discovery and design; and indeed nsp14 and nsp16 seem to play an important role in viral replication [11, 17, 30] . Accordingly, we set up sensitive inhibition tests for both activities, validated by low IC 50 values of known AdoMetdependent MTase inhibitors. Moreover, we show that aurintricarboxylic acid (ATA), which was shown to inhibit SARS-CoV replication [41] , targets both MTases indeed.
Results
SARS-CoV nsp14 is active as AdoMet-dependent N7-MTase on short capped RNA substrates whereas the nsp16 29O-MTase requires nsp10 as co-factor Unlike flaviviruses, which use a single active site in the NS5 protein for both N7-and 29O-MTase activities [32, 42] , coronaviruses presumably encode two separate MTases that catalyze the last two steps in the formation of a methylated RNA-cap structure. SARS-CoV nsp14 has been shown to be an RNA-cap N7-MTase [17] . Sequence motifs that are canonical in 29O-MTases were identified in nsp16 [3, 19] , but the experimental verification of the MTase activity has not been reported, in contrast to FCoV nsp16, for which a rather low activity could be demonstrated [18] . SARSCoV nsp10 was previously shown to interact with both nsp14 and nsp16 [35, 36] , suggesting its involvement in RNA capping and/or methylation. Consequently, we cloned and expressed both nsp10 and nsp16 in E. coli and purified both recombinant proteins, using their N-terminal His 6 -tag, by metal affinity chromatography. Nsp14 was expressed as a fusion protein with an intein tag at its Cterminus. The nsp14-intein product was bound to a chitin affinity column and the untagged protein was eluted after removal of the tag by DTT treatment. All three proteins were further purified by size exclusion chromatography. Upon SDS-PAGE, the purified proteins migrated as single bands corresponding to their expected molecular masses (nsp14: 57 kDa; His 6 -nsp16: 35 kDa, and His 6 -nsp10: 15 kDa) (Figure 2A ). The identity of the recombinant proteins was confirmed by trypsin digestion and mass spectrometry ((MALDI-TOF), data not shown). Figure 2B shows that nsp14 methylated GpppAC 5 in a time-dependent manner whereas neither nsp16 nor nsp10 alone did. Apparently, the activity of nsp14 was barely influenced by the presence of nsp10 or nsp16. In addition, we observed that nsp14 did not methylate 7Me GpppAC 5 ( Figure 2C ) suggesting that nsp14 methylates only the N7-position of the cap structure. In contrast to nsp14, nsp16 catalyzed methyltransfer to neither GpppAC 5 nor to 7Me GpppAC 5 under these reaction conditions. Surprisingly, when nsp16 activity assays were supplemented with nsp10, robust methylation of 7Me GpppAC 5 was observed ( Figure 2C ), but not of GpppAC 5 ( Figure 2B ). In control reactions, containing either nsp10 alone or nsp10 supplemented with nsp14 no 7Me GpppAC 5 -specific MTase activity was detected ( Figure 2C ). When the GpppAC 5 substrate was incubated with a combination of nsp10, nsp14, and nsp16 ( Figure 2B ) , the level of substrate methylation was enhanced compared to reactions performed with nsp14 alone. After overnight incubation of GpppAC 5 with the three proteins, the methyl incorporation reached a plateau and the incorporation level was twice higher than after a reaction in the presence of nsp14 alone (not shown). In contrast, no significant difference was observed between the methylation level reached after incubation of the 7Me GpppAC 5 substrate with either all three proteins or the nsp16-nsp10 pair only ( Figure 2C ). Taken together, these results suggest that, (i) SARS-CoV nsp14 methylates GpppAC 5 at the N7-position of the cap guanine and indeed acts as an N7-MTase on these substrates, (ii) nsp16 acts as an nsp10-dependent 29O-MTase on 7Me GpppAC 5 , (iii) the 29O-MTase activity of nsp16-nsp10 requires the presence of a cap structure already methylated at its N7-position and (iv) nsp14 and the nsp16-nsp10 pair can perform sequential double methylation of GpppAC 5 , presumably at the N7-and 29O-positions.
To determine how nsp10 stimulated nsp16 MTase activity, we co-expressed in E. coli an N-terminally Strep-tagged nsp10 and a His 6 -tagged nsp16. The bacterial cell lysate containing these proteins was incubated with Strep-Tactin beads (see Materials and Methods), in order to bind the tagged nsp10. After extensive washing, the proteins bound to the beads were analysed using SDS-PAGE. Figure 2D indicates that nsp16 remained associated with nsp10, whereas nsp16 alone was unable to bind to the beads. These data suggest that nsp10 can stimulate the MTase activity of nsp16 by direct association resulting in the formation of a nsp10/ nsp16 complex. When the intensities of the bands corresponding to nsp10 and nsp16 were quantified, a ratio of nsp10 to nsp16 of 1.1 was obtained. Correcting for the respective molecular masses, and assuming that they bind Coomassie blue dye with the same affinity, this yields a nsp10 to nsp16 ratio of about 2.3. This suggests that the complex does not contain a large molar excess of nsp10, as one might have expected due to the fact that nsp10 seems to form dodecamers under certain conditions [38] .
mRNA cap N7-and 29O-site specific methylation by SARS-CoV nsp14 and nsp10/nsp16
In order to test MTase activities of nsp14 and nsp10/nsp16 on virus-specific capped RNA substrates, we synthesized a 59-triphosphate-carrying RNA corresponding to the first 264 nucleotides of the SARS-CoV genome using the T7 RNA polymerase. Since the canonical T7 promoter inefficiently directs transcription of RNA beginning with an A, as is required to make transcripts resembling the 59 end of coronavirus RNAs, we used the T7 class II w2.5 promoter [43] . Additionally, we introduced a URG substitution in the 2 nd position of the RNA to increase the in vitro transcription efficiency (data not shown). The RNA was capped with [a-
32 P]-GTP using the vaccinia virus (VV) capping enzyme (containing RTPase, GTase and N7-MTase activities, see Materials and Methods) in the presence or absence of the methyl donor AdoMet. The substrates GpppAG-SARS-264 and 7Me GpppAG-SARS-264 were then incubated with various combinations of nsp14, nsp16, and nsp10. Reaction products were digested by nuclease P1 in order to release the RNA cap structure. Radiolabeled cap molecules were subsequently separated on TLC plates and visualized using autoradiography. The comparison with commercially available and in-house synthesized cap analogs allowed the identification of the methylation position of the cap structure. Figure 3A shows that the cap structure released after nuclease P1 digestion of substrates GpppAG-SARS-264 and 7Me GpppAG-SARS-264 RNA co-migrated, as expected, with GpppA and 7Me GpppA cap analogs, respectively. In the presence of nsp14, or the VV:N7-MTase positive control, the GpppA cap structure present at the 59 end of the RNA was converted into 7Me GpppA (left panel of Figure 3A ). We also observed that the methylation of the N7-position induced by nsp14 was weakly stimulated in the presence of nsp10, but was not influenced by the presence of nsp16. Indeed, nsp14 converts 83% of the substrate into the 7Me GpppA product, whereas in the presence of nsp10 97% of the substrate was converted, as judged by autoradiography analysis. Nsp10 or nsp16 alone did not show any MTase activity. When all three proteins are present, the substrate is fully methylated at the N7-and 29O-positions of the cap, as judged by the comparison with products generated by the bifunctional N7-and 29O-MTase domain of dengue virus protein NS5 (DV:NS5MTase), which was used as a positive control [32, 42] . The right panel of Figure 3A shows that incubation of 7Me GpppAG-SARS-264 RNA, with nsp14, nsp16 or nsp10 alone did not result in 29O-methylation of the 7Me GpppA structure. The same was true when nsp14/nsp10 or nsp14/nsp16 combinations were tested. In contrast, 29O-methylation of the cap structure of 7Me GpppAG-SARS-264 occurred upon incubation with nsp10/ nsp16, and also when all three proteins were used together. We therefore conclude that capped RNA corresponding to the first 264 nucleotides of the SARS-CoV genome represents a bona fide substrate to follow the RNA cap MTase activities of SARS-CoV nsp14 and nsp10/nsp16. Moreover, the TLC analysis allowed us to demonstrate that nsp14 indeed specifically methylates RNA cap structures at the N7-position and that nsp10/nsp16 methylates capped RNA at the 29O-position of the first nucleotide after the N7-methylated cap. As also observed when using short substrates, nsp10/nsp16 could only methylate 7Me GpppAG-SARS-264 and not GpppAG-SARS-264, suggesting that N7-methylation by nsp14 must precede 29O-methylation by nsp10/nsp16. We conclude that nsp14 exhibits N7-MTase activity in the absence of nsp10, whereas the latter is an absolute requirement for nsp16-mediated 29O-methylation of the cap structure. Nsp10, which was previously shown to interact with both nsp14 and nsp16 [35, 36] , modestly stimulates the nsp14-mediated cap N7-MTase activity (Figure 3A and S1B; 10 to 15% increase of activity at a broad optimum around a 4-fold molar excess). In order to directly monitor the order of SARS-CoV RNA-cap methylation, we performed a time-course experiment using the GpppAG-SARS-264 substrate in conjunction with nsp10, nsp14, and nsp16. The results, shown in Figure 3B , indicate that methylation of the substrate indeed starts at the N7-position. Subsequently, the 7Me GpppA cap-0 structure is converted to an 7Me GpppA 2'OMe cap-1 structure. A GpppA 2'OMe structure was never observed in this assay, not even when using larger amounts of nsp10/nsp16 or nsp16 (data not shown), in agreement with the data presented in Figures 2B and 3A that show that GpppAC 5 and GpppAG-SARS-264 substrates are not methylated by nsp10/ nsp16. Thus, the N7-methylation of the SARS-CoV cap structure by nsp14 is a pre-requisite for its recognition by the nsp10/nsp16 pair, which then converts the cap-0 into a cap-1 structure by 29O-methylation.
The nsp14 D 331 residue is essential for N7-methylation whereas catalytic residues of the N-terminal exonuclease domain are not
The recent identification of the C-terminal domain of nsp14 as an N7-MTase [17] revealed that this replicase subunit is a multifunctional protein, since it also carries an exoribonuclease activity embedded in its N-terminal domain [16] . The interplay between these two functionalities was analyzed using mutagenesis experiments. We mutated conserved residues in both the MTase and the exoribonuclease domain to evaluate the possible interplay or long-range regulation of both activities. The conserved residue D 331 , which is presumably involved in AdoMet-binding, was mutated to alanine. In the exoribonuclease domain, we replaced conserved residues from exonuclease motifs I (D 90 XE All the His-tagged nsp14 mutant proteins could be expressed, except the D243A mutant, which was barely soluble. Figure 4A shows that they migrated at a molecular mass similar to that of wt nsp14 upon SDS-PAGE. We next analyzed their N7-MTase activity on GpppAC 5 using [
3 H]-AdoMet as methyl donor. The results show that the D331A point mutation completely abolished nsp14 N7-MTase activity. This is in agreement with the hypothesis [17] that the MTase domain is located in the Cterminal half of nsp14 protein and that the conserved residue D 331 is important for N7-MTase function. In contrast, the mutations in the exonuclease domain did not significantly interfere with nsp14 MTase activity, excepted in the case of the motif I-double mutant (D 90 XE 92 ) which displayed attenuated N7-MTase activity (,2-fold). This observation is in agreement with the fact that a Nterminal truncation of 90 amino acids of the nsp14 exoribonuclease domain abolished the N7-MTase activity in a yeast transcomplementation assay [17] . Thus an altered N-terminus of the exoribonuclease domain may still interfere with the MTase activity to a certain extent.
Identification of K 46 -D 130 -K 170 -E 203 as a catalytic tetrad in SARS-CoV nsp16
In order to ascertain that nsp16 supports the 29O-MTase activity and not the nsp10 protein, we engineered and characterized a set of nsp16 point mutations. We mutated the conserved residues K 46 -D 130 -K 170 -E 203, which form the canonical catalytic tetrad of mRNA cap 29O-MTases [42, 44] . The putative catalytic residues of SARS-CoV nsp16 were identified using sequence alignment with the homologous FCoV nsp16 29O-MTase and other family members [18] . Three of the four alanine point mutants could be expressed as efficiently as wt nsp16, allowing their purification to homogeneity using a single-step of affinity chromatography (see Materials and Methods). Still, smaller amounts of the fourth mutant (K46A) could also be produced and purified. We obtained sufficient soluble protein to perform MTase assays, although protein yield and purity were lower than for the other mutants ( Figure 4B ). For all mutant proteins, the 29O-MTase activity was tested on 7Me GpppAC 5 and compared to that of the wt nsp16/nsp10 control pair. The 29O-MTase activity was indeed completely abolished by any single mutation of the putative K 46 -D 130 -K 170 -E 203 catalytic tetrad residues of nsp16. This result demonstrated that although nsp10 stimulates the 29O-MTase activity by a yet unknown mechanism, the catalytic activity itself resides in nsp16.
Inhibition of MTase activities of SARS-CoV nsp14 and nsp16/nsp10
Viral MTases exhibit many original features relative to their host cell MTase counterparts, and are increasingly explored as putative targets for the development of antivirals [45] . In order to set up sensitive N7-and 29O-MTase inhibition tests, we determined more precisely the conditions to measure optimum MTase activity for nsp14 and nsp16/nsp10 using their respective substrates GpppAC 5 and 7Me GpppAC 5 (see Text S1). We thus defined the following standard assay conditions: the N7-MTase activity of nsp14 was measured in presence of 40 mM Tris-HCl, pH 8.0 and 5 mM DTT. For the 29O-MTase assays, the same buffer was used together with 1 mM of MgCl 2 . As Figure S1B illustrates, nsp10 stimulates nsp16 29O-MTase activity in a dosedependent manner. We used a 6-fold molar excess of nsp10 over nsp16 corresponding to <75% of the maximal stimulation that could be achieved.
Inhibition was tested for two AdoMet analogs with documented mRNA cap MTase inhibition properties: AdoHcy (S-adenosyl-lhomocysteine), the co-product of methyl transfer, and sinefungin [18, 46, 47, 48, 49] . We also used compounds known to target other AdoMet-dependent MTases, such as SIBA, 3-deaza-adenosine [50] and MTA [51] . Based on their adenosine or guanosinecontaining structures, adenosine-and AdoMet-analogs 29,39,59-tri-O-acetyl-adenosine and S-59-adenosyl-L-cysteine were tested as well as GTP, 7Me GTP, GTP-or cap-analogs (ribavirin and its triphosphate as well as EICAR-triphosphate, GpppA and 7Me GpppA). Finally, we included two inhibitors of flavivirus mRNA cap MTase activites: aurintricarboxylic acid (ATA), which is expected to bind to the MTase active site [52] , and a substituted adamantane compound supposedly binding to the AdoMetbinding site [53] . Interestingly, ATA has been shown recently to inhibit SARS-CoV replication by an unknown mechanism of action [41] .
Nsp14 and nsp16/nsp10 were first incubated with 100 mM of each candidate inhibitor in the presence of [ GpppA) showed limited (50%) inhibition capacity on both SARS-CoV MTases. In contrast, we observed that AdoHcy, sinefungin and ATA efficiently inhibited both enzymes at 100 mM. The IC 50 values of AdoHcy were 16 and 12 mM for the N7-and 29O-MTase activities, respectively ( Figure 5B) ten-fold higher than Ki values reported for VV:N7-and 29O-MTases (1 and 0.5 mM, respectively, [47] ). Sinefungin, a potent inhibitor of VV:N7-and 29O-MTases with reported IC 50 values of 12.0 and 39.5 nM, respectively [46] , showed the most potent inhibition profile on nsp14 and nsp10/nsp16 with IC 50 values of 496 nM and 736 nM, respectively ( Figure 5C) . These values are similar to the IC 50 value reported for the inhibition of the 29O-MTase activity of DV:NS5MTase (420 nM [49] and 630 nM [48] ). The obtained IC 50 values of ATA for SARS-CoV nsp14 and nsp10/nsp16 were 6.4 mM and 2.1 mM, respectively ( Figure 5D ). These results demonstrate that sensitive assays are now available to discover and characterize inhibitors of the SARS-CoV N7-and 29O-MTases rendering low IC 50 values of known AdoMet-dependent MTase inhibitors like AdoHcy and sinefungin. Moreover we have shown that nsp14 and nsp16 MTases are two putative targets of ATA, that was shown to inhibit SARS-CoV replication in infected cells [41] . 2 mM) . The methyl transfer to the RNA substrate was measured after 30 min by using a filter-binding assay. The 29O-MTase activity of the wt protein in the presence of nsp10 was arbitrarily set to 100%. The bar graph represents the mean of 3 independent experiments. The purified His 6 -tagged proteins analyzed by SDS-PAGE (14%) are shown in the lower panel. doi:10.1371/journal.ppat.1000863.g004
Discussion
Enzymatic activities postulated to be involved in the SARS-CoV RNA capping pathway were previously documented for the ORF1b-encoded replicase subunits nsp13 (RNA 59-triphosphatase/helicase [13] ) and nsp14 (N7-MTase [17] ). Thus far, the predicted 29O-MTase activity of nsp16 [3, 19] could only be verified for FCoV nsp16 [18] . Surprisingly, SARS-CoV nsp16 29O-MTase failed to exhibit activity under a wide range of experimental conditions, including those used for FCoV nsp16 (not shown). In this study, we have characterized the MTase activities of both SARS-CoV nsp14 and nsp16, and in particular established that the in vitro activity of SARS-CoV nsp16 critically depends on the presence of nsp10. The latter had no known role or function, but was previously shown to interact with both MTase proteins nsp14 and nsp16 [35, 36] .
Here, we show that the nsp14 AdoMet-dependent MTase activity can methylate GpppAC 5 RNA, but not a 7Me GpppAC 5 substrate, indicating that nsp14 specifically targets the N7-position of the guanine residue in the cap structure. This was verified using a substrate mimicking the capped 59 end of the SARS-CoV genome. Nuclease P1 enzymatic digestion and TLC analysis confirmed the position of methylation by nsp14; and mutagenesis of a predicted AdoMet binding site residue abolished N7-MTase activity. We therefore conclude that nsp14 alone can act as an AdoMet-dependent MTase that specifically targets the N7-position of the cap structure, thus converting GpppRNA into 7Me GpppRNA. These results confirm and extend the recently described observations on the cap N7-MTase activity of SARSCoV nsp14 in vitro and in a yeast-based complementation system [17] .
In contrast to nsp14, bacterially expressed SARS-CoV nsp16 is less stable, reluctant to crystallization (not shown), and inactive on 7Me GpppRNA and GpppRNA in our in vitro assays. We report here that SARS-CoV nsp16 forms a complex with nsp10 that is endowed with robust and long-lived MTase activity. In contrast, FCoV nsp16 by itself was shown to possess 29O-MTase activity under similar reaction conditions, but at much higher enzyme concentration (SARS-CoV: 200 nM; FCoV: 3 mM [18] ). This suggests that FCoV nsp16 might also need FCoV nsp10 for its proper activation. As in the case of FCoV nsp16, SARS-CoV nsp16 in the presence of nsp10, specifically methylates capped RNAs carrying a methyl group at the N7-guanine position, allowing the conversion of cap-0 into cap-1 structures. Using 7Me GpppAG-RNA corresponding to the 59 end of the SARS-CoV genome, we have confirmed that nsp10/nsp16 catalyzes the transfer of a methyl group from the AdoMet donor to the 29O- [3, 18, 19] .
The interplay between nsp10 and the nsp16 MTase
The nsp10 protein was previously proposed to play a role in viral RNA synthesis [11, 39, 40] and replicase polyprotein processing [40] on the basis of the analysis of MHV nsp10 mutants. In this work, we propose a new function for nsp10 as a regulator of an enzyme involved in the methylation of cap structures. Our observation seems not directly related to the phenotype previously described for nsp10 mutants [11, 39, 40] . Nevertheless, RNA cap methylation defects should limit RNA stability and may therefore contribute to a decrease in viral RNA synthesis observed in MHV mutants [11, 39, 40] . Here, we show that nsp10 itself is catalytically inert in methylation reactions (Figures 2, and 3) and that it forms a complex with nsp16 ( Figure 2C ). Interestingly, whereas at least a 10-fold molar excess of nsp10 is required for maximal stimulation of nsp16 ( Figure S1B) , quantification of the protein bands of nsp10 and nsp16 in the purified complex indicates a maximum ratio of 2.3 ( Figure 2D ). We assume that, under conditions of maximal stimulation, nearly all nsp16 molecules are associated with one or two nsp10 molecules. Considering that the reaction mixture at 50% stimulation contained 200 nM of nsp16 and around 400 nM of nsp10 ( Figure S1B ), the dissociation constant of the nsp10/ nsp16 complex can roughly be estimated to be in the order of 400 nM for a 1:1 complex or 200 nM for a 2:1 complex. This is in agreement with a K d of 250 nM determined by plasmon surface resonance analysis (Lecine P. personal communication).
What could be the mechanism of nsp16 activation by nsp10? Nsp10 may increase the stability of nsp16, stabilize the nsp16 RNA binding groove, contribute to RNA substrate binding and/ or allosterically regulate its substrate affinity and activity. Similar activation of an MTase involved in the capping pathway was previously reported for the VV capping enzyme [54] . The catalytic efficiency of the N7-MTase domain of the VV:D1 protein was 370-fold stimulated by addition of an equimolar concentration of the small VV:D12 protein, which does not contain any catalytic residues [55] . Activation is achieved through increase of substrate and co-substrate affinity as well as of the turn over number. At the same time, VV:D12 exerts a stabilizing effect on VV:D1 [55] . The determination of the crystal structure of the protein complex VV:D1/D12 [56] revealed that the VV:D12 protein is structurally homologous to the cap 29O-MTase of reovirus, with a truncation of the AdoMet binding domain. The SARS-CoV nsp10 crystal structure did not reveal any similarity to an MTase fold nor to any protein in the Protein Data Bank (PDB) [37, 38] , but the activating effect of nsp10 on nsp16 might also be exerted on different levels via allosteric activation by increasing substrate affinity and/or turn over number, and/or by stabilization of nsp16.
The presence of two Zn fingers is a major structural feature of nsp10 that is likely related to its biological functions, since Zn fingers typically function as interaction modules binding to proteins, nucleic acid and small molecules [57] . Interestingly, several MTases have previously been shown to be regulated through specific interactions with Zn finger domains [58, 59] . Since the first Zn finger of nsp10 lies in a positively charged surface patch, it might be involved in the low affinity interaction of nsp10 with single-and double-strand RNA and DNA [37] . The affinity of nsp10 for single-stranded RNA appears too weak to explain a direct role in RNA recruitment for nsp16 [36] . We expect that SARS-CoV nsp16 contains a specific binding site for a cap-0 structure followed by a small stretch of 3 to 4 nucleotides as predicted for FCoV nsp16 from enzymatic assays [18] . The formation of the complex nsp10/nsp16 might provide a longer substrate-binding site and in that way enhance affinity of nsp16 for its RNA substrate. Nevertheless, given the fact that the full activation effect by nsp10 is also seen when short substrates containing the cap and 5 nucleotides are used, we surmise that extension of the RNA binding site is of minor importance. Further work is needed in order to understand the molecular basis of nsp16 activation by nsp10.
Coronavirus mRNA cap methylation
There are indications that CoV genomic RNAs and subgenomic RNAs carry a 59-terminal cap-1 structure (see Introduction) and three of four putative cap-forming enzyme functions required to produce this structure have now been identified for SARS-CoV (nsp13, nsp14, and nsp16) [3, 17, 18] . The CoV cap structure methylation seems to follow the ''classic'' sequence of N7-methylation preceding the 29O-methylation. The modular structure of two separate single-domain enzymes corresponds to the scenario in metazoan and plants [25, 26] . It contrasts to dsRNA reoviruses where one multi-domain protein contains two MTase domains [60] and to flaviviruses and negative-strand RNA ((-) RNA) vesiculoviruses where both MTase activites reside in a single domain of larger proteins and use a single active site [32, 61] . A characteristic feature of CoV MTases is that nsp14 recognizes non-methylated RNA cap exclusively, and nsp10/nsp16 recognizes N7-methylated RNA cap exclusively. In contrast, bifunctional MTases recognize both non-methylated and methylated cap structures with equal affinity [48, 62, 63] . Interestingly, the flaviviral N7-MTase activity is regulated by specific 59-proximal viral RNA secondary structures and both N7-and 29O-MTase activities seem to require in particular the terminal dinucleotide AG [32, 64] . Since the SARS-CoV nsp14 N7-MTase activity can complement N7-MTase defects in yeast, [17] , it suggests that specific sequences and/or RNA structures are not required for this activity. This was confirmed in our in vitro assays, where both N7-and 29O-methylation was observed using small GpppAC 5 RNA substrates that do not correspond to the natural sequence present at the 59 end of CoV mRNAs. Nevertheless, the CoV capping machinery is likely to act specifically on viral mRNA substrates, which present a common 59-terminal leader sequence (72 nucleotides long in the case of SARS-CoV [4] ). The mechanism to achieve this selectivity may depend on the GTase reaction or on the fine regulation of capping enzymes by protein-protein interactions within the replication and transcription complex. The regulation of the 29O-MTase activity of nsp16 by the small nsp10 protein is clearly an original feature of CoV mRNA cap methylation.
Coronavirus MTases as potential targets for antiviral inhibitors
Virally encoded RNA cap N7-and 29O-MTase activities have been identified in various virus families, such as dsDNA poxviruses [65, 66] , dsRNA reoviruses [67, 68] , (-) RNA viruses such as vesicular stomatitis virus [61] , and (+) RNA viruses like flaviviruses [33, 42, 69] . For many of them, including coronaviruses [17, 30] , it has been shown that mutations abolishing the N7-MTase activity have a clear detrimental effect on replication [32] , whereas 29O-MTase knockouts exerted more moderate effects [32, 33] . These observations suggest that compounds specifically inhibiting cap MTases could be potent antiviral agents. Although some viral MTase inhibitors have also been reported to inhibit mammalian MTases [70, 71] , sinefungin or other AdoMet analogs might have higher specificity towards viral MTases. Accordingly, it has been shown that sinefungin inhibits fungal mRNA cap N7-MTases with 5 to 10 times more potency than the human isoform [71] .
Here, we report assays using GpppAC 5 and 7Me GpppAC 5 substrates that constitute sensitive screening tests for the identification and characterization of inhibitors of the N7-and 29O-MTase activities, respectively, of SARS-CoV. We confirmed this by obtaining low IC 50 values of known AdoMet-dependent MTase inhibitors AdoHcy and sinefungin. Furthermore, we found that ATA, a compound previously reported as a putative blocker of the catalytic site of NS5MTase of flaviviruses [52] , and of SARS-CoV replication in infected cells [41] , inhibited both SARS-CoV MTase activities with IC 50 values of 2.1 and 6.4 mM, respectively. Thus, we propose that nsp14 and nsp16/nsp10 are two of the SARS-CoV targets of ATA leading, or at least contributing, to the inhibition of SARS-CoV replication.
In conclusion, our results identify and characterize the main viral protein players of SARS-CoV mRNA cap methylation. Its specificity and mechanistic originality remain unparalleled thus far and should open new avenues to investigate viral RNA capping, a field that is increasingly permeable to drug design projects.
Materials and Methods

Reagents
AdoMet and cap analogs GpppA and [18, 52, 53] and ATA was dissolved in 0.1 M NaOH as described in [52] . Concentrations were set to 10 mM and compounds stored at -20uC. All radioactive reagents were purchased from Perkin Elmer.
Cloning of the SARS-CoV nsp10, nsp14 and nsp16 genes
The SARS-CoV nsp10-, nsp14-, and nsp16-coding sequences were amplified by RT-PCR from the genome of SARS-CoV Frankfurt-1 (accession number AY291315) as previously described [72] . The nsp10, nsp14, and nsp16 genes (encoding residues 4231-4369, 5903-6429, and 6776-7073 of replicase pp1ab) were cloned using Gateway technology (Invitrogen) into expression vector pDest14 (pDest14/6His-nsp10, pDest14/6His-nsp14 and pDest14/6His-nsp16) to produce recombinant proteins carrying an N-terminal His 6 -tag. The nsp14 gene was also cloned into the pTXB1 vector from the Impact kit (New England Biolabs) to generate the pTXB1-nsp14 plasmid that allows the expression of the nsp14 protein fused to the intein-chitin binding domain.
SARS-CoV nsp10/nsp16 complex was produced in E. coli in a bi-promotor expression plasmid kindly provided by Bruno Coutard (AFMB France). In this backbone, SARS CoV nsp10 can be expressed under a tet promoter and encodes a protein in fusion with a N-terminal strep tag, whereas nsp16 is expressed under a T7 promoter and encodes a protein in fusion with a Nterminal hexa-histidine tag. The single point mutants of pDest14/ 6His-nsp14 (the mutant numbering starts at the beginning of the nsp14 sequence; D90A & E92A, H268A, H268L, D273A and D331A) and the mutants of pDest14/6His-nsp16 (the mutant numbering starts at the beginning of the nsp16 sequence; K46A, D130A, K170A, E203A) were generated by PCR using the Quickchange site-directed mutagenesis kit (Stratagene), according to the manufacturer's instructions.
Expression and purification of SARS-CoV nsp10, nsp14 and nsp16 proteins E. coli C41 (DE3) cells (Avidis SA, France), containing the pLysS plasmid (Novagen), were transformed with the various expression vectors and grown in 2YT medium containing ampicillin and chloramphenicol. Protein expression was induced by addition of IPTG to a final concentration of 500 mM (nsp10) or 50 mM (nsp14 and nsp16), when the OD 600 nm value of the culture reached 0.5. Nsp10 expression was performed during 4 h at 37uC, whereas nsp14-and nsp16-expressing bacteria were incubated during 16 h at 17uC. Bacterial cell pellets were frozen and resuspended in lysis buffer (50 mM HEPES, pH 7.5, 300 mM NaCl, 5 mM MgSO 4 , 5 mM b-mercaptoethanol (only for nsp10) supplemented with 1 mM PMSF, 40 mM imidazole, 10 mg/ml DNase I, and 0.5% Triton X-100. After sonication and clarification, proteins were purified by two steps of chromatography except the nsp14 mutants, which were purified by one-step of IMAC (HisPurTM Cobalt Resin; Thermo Scientific) and concentrated on 50-kDa centrifugal filter units (Millipore). Two-step purification of the His 6 -tagged proteins started with IMAC (HisPurTM Cobalt Resin; Thermo Scientific) eluting with lysis buffer supplemented with 250 mM imidazole. Protein fractions were then loaded on a HiLoad 16/60 Superdex 200 gel filtration column (GE Healthcare), and eluted with 10 mM HEPES, pH 7.5, 150 mM NaCl. The protein fractions were concentrated to around 2 mg/ml and stored at 220uC in the presence of 50% glycerol.
The nsp14 protein expressed in fusion with the intein-chitin binding domain was purified on a chitin column using the IMPACT kit (New England Biolabs). The bacterial lysate was loaded onto the column, washed with 50 mM HEPES pH 7.5, 1 M NaCl and 0.5% Triton X-100. The column was then incubated in 50 mM HEPES pH 7.5, 500 mM NaCl, 50 mM DTT at 4uC for 48 hours in order to induce the intein cleavage. Next, the protein was eluted in 50 mM HEPES pH 7.5, 1 M NaCl buffer and subsequently purified on a HiLoad 16/60 Superdex 200 gel filtration column (GE Healthcare) as describe above. The identity of each of the purified proteins was confirmed by MALDI-TOF after trypsin digestion.
SARS-CoV nsp10/nsp16 co-expression was performed in E. coli strain C41 (DE3) (Avidis SA, France) transformed with the pLysS plasmid (Novagen). Cultures were grown at 37uC until the OD 600nm reached 0.6. Expression was induced by adding 50 mM IPTG and 200 mg/L of anhydrotetracycline; then cells were incubated for 16 h at 24uC. Bacterial pellets were treated as given above and the soluble protein fraction incubated with StrepTactin sepharose (IBA Biotagnology). After 3 washes, bound proteins were eluted with 2.5 mM D-desthiobiotin in binding buffer. After analysing the purified protein complex by SDS-PAGE, the intensities of Coomassie-stained bands were quantified using ImageJ.
RNA synthesis and purification
Short capped RNAs ( 7Me GpppAC 5 , GpppAC 5 , were synthesized in vitro using bacteriophage T7 DNA primase and were purified by high-performance liquid chromatography (HPLC) as previously described [69] .
RNA substrate corresponding to the 59-terminal 264 nucleotides of the SARS-CoV genome (59 SARS-264) was prepared as follows. The 59 UTR of the SARS-CoV genome Frankfurt-1 was amplified by PCR using the primers BamH1-T7phi2.5-59SARS (s) (CGGGATC-CCAGTAATACGACTCACTATTATATTAGGTTTTTACCT-ACCC) and EcoRI-SARS-264 (as) (GGAATTCCTTACCTT-TCGGTCACAC) and cloned in the pUC18 (Fermentas) plasmid after BamHI/EcoRI restriction-ligation procedure. The T7 class II W2.5 promoter [43] was used (underlined in the primer) and the second nucleotide of the genome (U) was substituted by a G. The transcription matrix, was amplified by PCR (primers BamH1-T7phi2.5-59SARS-AG (s) (CGGGATCCCAGTAATACGACT-CACTATTAGATTAGGTTTTTACCTACCC) and SARS-264 (as) (CTTACCTTTCGGTCACAC)) and purified on agarose gel using the QIAquick gel extraction kit (Qiagen). The AG-SARS-264 RNA substrate was synthesized by in vitro transcription using the MEGAshortscript T7 RNA polymerase kit (Ambion). After DNase treatment (Ambion), and purification by RNeasy mini kit (Qiagen), the AG-SARS-264 RNA was incubated for 1 h at 37uC with the VV capping enzyme (ScriptCap m7G Capping kit, Epicentre Biotechologies) in a reaction volume of 20 ml, either in the absence or in the presence of AdoMet, according to the instructions of the manufacturer. 10 mCi [a- GpppAG-SARS-264 were then purified with the RNeasy mini kit (Qiagen).
Radioactive methyltransferase and filter binding assay
MTase activity assays were performed in 40 mM Tris-HCl, pH 8.0, 5 mM DTT, 1 mM MgCl 2 (only for nsp16/nsp10), 2 mM 7Me GpppAC 5 or GpppAC 5 , 10 mM AdoMet, cand 0.03 mCi/ml [ 3 H]AdoMet (GE Healthcare). In the standard assay, nsp10, nsp14, and nsp16 were added at final concentrations of 1.2 mM, 50 nM, and 200 nM, respectively. The final concentrations of nsp14 and nsp16 used in the assays were chosen so as to stay in the linear phase of product formation after a 1 h incubation when using GpppAC 5 or 7Me GpppAC 5 as substrates. A 6-fold molar excess of nsp10 over nsp16 was chosen to achieve about 75% of the maximal stimulation of 29O-MTase activity. Under these conditions, the nsp14 and nsp10/nsp16 methylation reactions converted similar amounts of substrate after 1 h of reaction. No sign of protein inactivation was found up to the apparent end of the linear phase. Reaction mixtures were incubated at 30uC and stopped after the indicated times by a 10-fold dilution of the reaction mixture in 100 mM ice-cold AdoHcy. Samples were kept on ice and then transferred to glass-fiber filtermats (DEAE filtermat; Wallac) by a Filtermat Harvester (Packard Instruments). Filtermats were washed twice with 0.01 M ammonium formate, pH 8.0, twice with water, and once with ethanol, dried, and transferred into sample bags. Betaplate Scint (Wallac) scintillation fluid was added, and the methylation of RNA substrates was measured in counts per minute (cpm) by using a Wallac 1450 MicroBeta TriLux liquid scintillation counter. For inhibition assays, we set up the reactions as described above with 7Me GpppAC 5 for nsp16 and GpppAC 5 for nsp14 in the presence of 100 mM inhibitor candidate. Enzymes and RNA substrates were mixed with the inhibitor before the addition of AdoMet to start the reaction. The final concentration of DMSO in the reaction mixtures was below 5%, and control reactions were performed in presence of DMSO, which does not alter MTase activity. Reaction mixtures were incubated at 30uC for 4 h and analyzed by filter binding assay as described above. The IC 50 (inhibitor concentration at 50% activity) value of AdoHcy, sinefungin and ATA were determined using Kaleidagraph. Data were adjusted to a logistic dose-response function, % activity = 100/(1+[I]/IC 50 ) b , where b corresponds to the slope factor and [I] corresponds to the inhibitor concentration [73] .
MTase assay on SARS-264 RNA and cap-methylation analysis
MTase activity assays were performed in 40 mM Tris-HCl, pH 8.0, 5 mM DTT, 1 mM MgCl 2 (only for nsp16/nsp10), 50 mM AdoMet and 0.75 mM of capped AG-SARS-264 RNA at 30uC. The reaction was stopped after different reaction times by incubating samples for 5 min at 70uC. Samples were treated overnight with proteinase K (0.1 mg/ml, Invitrogen). Proteinase K was inactivated by addition of 5 mM PMSF; and the RNAs were subsequently digested for 4 h with nuclease P1 (0.05 U/ml, USBiological). Radiolabeled cap analog standards were produced by direct digestion of the substrates leading to GpppA and 7Me GpppA or digestion after methylation of the 29O-position using VV 29O-MTase (ScriptCap 29O-methyltransferase kit, Epicentre Biotechnologies) leading to GpppA 2'OMe and 7Me GpppA 2'OMe . Digestion products were separated on polyethyleneimine cellulose thin-layer chromatography (TLC) plates (Macherey Nagel) using 0.45 M (NH 4 ) 2 SO 4 as mobile phase. After drying TLC plates, the caps released by nuclease P1 were visualized using a phosphorimager (Fluorescent Image Analyzer FLA3000 (Fuji)).
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